Metastatic Colorectal Cancer: Management With Trifluridine/Tipiracil .
BACKGROUND
Treatment-related adverse events (AEs) are common in patients with metastatic colorectal cancer (mCRC) receiving chemotherapy. These AEs may affect patient adherence, particularly with completely oral regimens, such as trifluridine/tipiracil (TAS-102, Lonsurf®), an antimetabolite agent for patients with mCRC refractory or intolerant to standard therapies. .


OBJECTIVE
This article reviews strategies for promoting adherence and educating patients and caregivers about oral therapy with trifluridine/tipiracil.  .


METHODS
Recommended strategies for managing AEs are reviewed, with a focus on the most common AEs reported in patients with mCRC receiving trifluridine/tipiracil in clinical trials. .


RESULTS
Oncology nurses play an important role in educating and counseling patients regarding treatment and its potential side effects. Among patients with mCRC refractory or intolerant to standard therapies, trifluridine/tipiracil was found to have a favorable safety profile. It is associated with hematologic AEs as well as a low incidence of nausea, diarrhea, vomiting, anorexia, and fatigue.
Yale University.
Teresa
T
White
Yale New Haven Hospital.
Heidi
H
Larson
Yale University.
Alexandra
A
Minnella
Yale University.
Howard S
HS
Hochster
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced* / Q000188:drug therapy; D009362:Neoplasm Metastasis / Q000188:drug therapy; D014271:Trifluridine / Q000008:administration & dosage / Q000009:adverse effects*; D014839:Vomiting / Q000139:chemically induced* / Q000188:drug therapy*
D014271:Trifluridine
TAS-102; adverse effects; metastatic colorectal cancer ; trifluridine/tipiracil